S
SCYNEXIS D
D
SCYX
0.82000
USD
-0.01
(-1.20%)
مغلق
حجم التداول
0
الربح لكل سهم
-0
العائد الربحي
-
P/E
-1
حجم السوق
31,996,625
الأخبار المقالات
العنوان: SCYNEXIS
القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.